⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

April 1, 1998Journal of Clinical Oncology

Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099.

Muhyi Al‐Sarraf Michael LeBlanc Padmini Giri K.K. Fu Jay S. Cooper T. Vuong A A Forastiere George L. Adams Wael Sakr Dorit Elisabeth Schuller John F. Ensley

View at Publisher

Ask AI

Bookmark

Share

Ask about this paper

Answers are grounded in this paper and cite their sources.

Ask your own question…

Abstract

We conclude that chemoradiotherapy is superior to radiotherapy alone for patients with advanced nasopharyngeal cancers with respect to PFS and overall survival.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Al‐Sarraf et al. (1998) studied this question.

synapsesocial.com/papers/69d76f8303ad387f3548f36c https://doi.org/10.1200/jco.1998.16.4.1310

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 related papers. Consider them for comparative context:

1Stereotactic Ablative Radiotherapy Versus Surgical Resection for Early-Stage Non–Small Lung Cancer: An Emulated Target TrialJournal of Clinical Oncology · 2026
2Immunochemotherapy for Borderline Resectable or Locally Advanced Pancreatic Cancer: A Randomized Controlled TrialJournal of Clinical Oncology · 2026
3Methylphenidate for Hematologic Cancer–Related Fatigue: A Randomized Clinical TrialJournal of Clinical Oncology · 2026
4Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2026.3.4Journal of Clinical Oncology · 2026
5KEYNOTE-867: A Phase III, Randomized, Double-Blind Study of Stereotactic Body Radiotherapy With Pembrolizumab for Unresected Stage I or II Non–Small Cell Lung CancerJournal of Clinical Oncology · 2026

Darovasertib and Crizotinib First-Line Treatment for Metastatic Uveal Melanoma: Overall Survival, Efficacy, and Safety From the OptimUM-01 StudyJournal of Clinical Oncology · 2026
Art as a Shared Space: Tracing the Unseen Through a Body MapJournal of Clinical Oncology · 2026
PARP Inhibitors in the Management of Ovarian Cancer: ASCO Living Guideline, Version 2026.1.0Journal of Clinical Oncology · 2026
Dalmelitinib Plus Aumolertinib in Advanced NSCLC Patients With EGFR-TKI Resistance and MET Amplification: A Randomized Phase 3 TrialJournal of Clinical Oncology · 2026
COMPANION-002: A Randomized Phase 2/3 Trial of Tovecimig Plus Paclitaxel versus Paclitaxel Alone as a Second-line Therapy in Patients with Advanced Biliary Tract CancerJournal of Clinical Oncology · 2026

More from Journal of Clinical Oncology

More from Providence College